International Network for Comparison of HIV Neutralization Assays: The NeutNet Report

Fenyö EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, Donners H, Heyndrickx L, Alcami J, Bongertz V, Jassoy C, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Sattentau Q, Schuitemaker H, Sutthent R, Wrin T, Scarlatti G.

PLoS One 2009; 4:e4505.

Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference

Ross AL, Bråve A, Scarlatti G, Manrique A, Buonaguro L.

Lancet Infect Dis 2010; 10:305-16.

Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference

Wahren B, Biswas P, Borggren M, Coleman A, Da Costa K, De Haes W, Dieltjens T, Dispinseri S, Grupping K, Hallengärd D, Hornig J, Klein K, Mainetti L, Palma P, Reudelsterz M, Seifried J, Selhorst P, Sköld A, van Gils MJ, Uchtenhager H, Weber C, Shattock R, Scarlatti G.

J Transl Med 2010; 8:72.

Th2-polarization in peripheral blood mononuclear cells from HIV-infected subjects activated by HIV-VLPs

Buonaguro L, Tornesello ML, Gallo RC, Marincola FM, Lewis GK, Buonaguro FM.

J Virol 2009; 83:304-313.

Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTB-MPR

Matoba N, Kajiura H, Cherni,I, Doran JD, Bomsel M, Fujiyama K, Mor TS.

Plant Biotechnol J 2009; 7:129-145.

Impact of host cell variation on the neutralization of HIV-1 in vitro

Polonis VR, Schuitemaker H, Bunnik EM, Brown BK, Scarlatti G.

Curr Opin HIV AIDS 2009; 4:400-7.

Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation

Buonaguro L, Monaco A, Aricò E, Wang E, Tornesello ML, Lewis GK, Marincola FM, Buonaguro FM.

BMC Bioinformatics 2008; 9(Suppl 2):S5

Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection

Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H.

J Virol 2008; 82:7932-7941.

Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection

Cagigi A, Mowafi F, Phuong Dang LV, Tenner-Racz K, Atlas A, Grutzmeier S, Racz P, Chiodi F, Nilsson A.

Blood 2008; 112:4401-4410.

B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design

Cagigi A, Nilsson A, De Milito A, Chiodi F.

Vaccine 2008; 26:3016-3025.

Both lipid environment and pH are critical for determining physiological solution structure of 3-D-conserved epitopes of the HIV-1 gp41-MPER peptide P1

Coutant J, Yu H, Clement M-J, Alfsen A, Toma F, Curmi PA, Bomsel M.

FASEB J 2008; 22:4338-4351.

Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes

Matoba N, Griffin TA, Mittman M, Doran JD, Alfsen A, Montefiori DC, Hanson CV, Bomsel M, Mor TS.

Curr HIV Res 2008; 6:218-229.

Two amino acid substitutions within first external loop of CCR5 induce HIV blocking antibodies in mice and chicken

Pastori C, Clivio A, Diomede L, Consonni R, De Mori GMS, Longhi R, Colombo G, Lopalco L.

J Virol 2008; 82:4125-4134.

Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination

Polonis VR, Brown BK, Rosa Borges A, Zolla-Pazner S, Dimitrov DS, Zhang MY, Barnett SW, Ruprecht RM, Scarlatti G, Fenyö EM, Montefiori DC, McCutchan FE, Michael NL.

Virology 2008; 375:315-20.

Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection

Yu H, Tudor D, Alfsen A, Labrosse B, Clavel F, Bomsel M.

Retrovirology 2008; 5:93-105.

HIV neutralizing antibodies: relevance to pathogenesis and vaccines

Albert J, Chiodi F, Fenyö EM.

J Intern Med 2007; 262:2-4.

Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient

Bunnik EM, Quakkelaar ED, van Nuenen AC, Boeser-Nunnink B, Schuitemaker H.

J Virol 2007; 81:525-531.

DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity

Buonaguro L, Devito C, Tornesello ML, Schröder U, Wahren B, Hinkula J, Buonaguro FM.

Vaccine 2007; 25: 5968-5977.

HIV-1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications

Buonaguro L, Tornesello ML, Buonaguro FM.

J Virol 2007; 81:10209-10219.

Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies

Quakkelaar ED, van Alphen FP, Boeser-Nunnink BD, van Nuenen AC, Pantophlet R, Schuitemaker H.

J Virol 2007; 81:8533-8542.

Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro

Quakkelaar ED, Bunnik EM, van Alphen FP, Boeser-Nunnink BD, van Nuenen AC, Schuitemaker H.

Virology 2007; 363:447-453.

Biological and genetic evolution of HIV Type 1 in two siblings with different patterns of disease progression

Ripamonti C, Leitner T, Lauren A, Karlsson I, Pastore A, Cavarelli M, Antonsson L, Plebani A, Fenyo EM, Scarlatti G.

AIDS Res Hum Retrovir 2007; 23: 1531–1540.

Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses

Buonaguro L., Tornesello ML, Tagliamonte M, Gallo RC, Wang LX, Kamin-Lewis R, Abdelwahab S, Lewis GK, Buonaguro FM.

J Virol 2006; 80: 9134-9142.

Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate

Matoba N, Geyer BC, Kilbourne J, Alfsen A, Bomsel M, Mor TS.

Vaccine 2006; 24:5047-5055.

Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection

Titanji K, De Milito A, Cagigi A, Thorstensson R, Grützmeier S, Atlas A, Hejdeman B, Kroon FP, Lopalco L, Nilsson A, Chiodi F.

Blood 2006; 108:1580-1587.

Immune response in rhesus macaques after mixed modality immunizations with DNA, recombinant Adenovirus and recombinant gp120 from human immunodeficiency virus type 1

Vinner L, Therrien D, Wee E G-T, Laursen I, Hanke T, Corbet S, Fomsgaard A.

APMIS 2006; 114:690-699.

Induction of systemic and mucosal cross-clade neutralizing antibodies in Balb/c mice immunized with HIV-1 clade A virus-like particles administered by different routes of inoculation

Buonaguro L, Visciano ML, Tornesello ML, Tagliamonte M, Biryahwaho B, Buonaguro FM.

J Virol 2005; 79:7059-7067.

Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation.

Aricò E, Wang E, Tornesello ML, Tagliamonte M, Lewis GK, Marincola FM, Buonaguro FM, Buonaguro L.

J Transl Med 2005; 3:45-59.

CCR5 specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects

Barassi C, Lazzarin A. Lopalco L.

Blood 2004; 104:2205-2206.

A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs

Matoba N, Magerus A, Geyer BC, Zhang Y. Muralidharan M, Alfsen A, Arntzen CJ. Bomsel M, Mor TS.

Proc Natl Acad Sci USA 2004; 101:13584-13589.

Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from a primary solate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost

Vinner L, Wee E G-T, Patel S, Corbet S, Gao GP, Nielsen C, Wilson JM, Ertl HC J, Hanke T, Fomsgaard A.

J Gen Virol 2003; 84:203-213.

HIV-1 gp41 envelope residues 650-685 exposed on native virus acts as a lectin to bind epithelial cell galactosyl ceramide

Alfsen A, Bomsel M.

J Biol Chem 2002; 277:25649-25659.

Induction of neutralizing antibodies and CTLs in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A (HIV-VLPAs)

Buonaguro L, Racioppi L, Tornesello ML, Arra C, Visciano ML, Biryahwaho B., Sempala SDK, Giraldo G, Buonaguro FM.

Antiviral Res 2002; 54:189-201.

Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41

Clerici M, Barassi C, Devito C, Pastori C, Piconi S, Trabattoni D, Longhi R, Hinkula J, Broliden K, Lopalco L.

AIDS 2002; 16:1731-1741.

Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects

Devito C, Hinkula J, Kaul R, Kimani J, Kiama P, Lopalco L, Barassi C, Piconi S, Trabattoni D, Bwayo JJ, Plummer F, Clerici M, Broliden K.

J AIDS 2002; 30:413-420.

High efficient production of pr55gag virus-like particles expressing multipleHIV-1 epitopes, including a gp120 protein derived from an ugandan HIV-1 isolate of subtype A

Buonaguro L, Buonaguro FM, Tornesello ML, Mantas D, Beth-Giraldo E, Wagner R, Michelson S, Prevost M-C, Wolf H, Giraldo G.

Antiviral Res 2001; 49:35-47.

Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary CCR5-tropic, early HIV type 1 isolate (BX08) with human codons

Corbet S, Vinner L, Hougaard DM, Bryder K, Nielsen HV, Nielsen C, Fomsgaard A.

AIDS Res Hum Retrovir 2000; 16:1997-2008.

Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons

Vinner L, Nielsen HV, Bryder K, Corbet S, Nielsen C, Fomsgaard A.

Vaccine 1999; 17:2166-2175.

Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates

Scarlatti G, Albert J, Rossi P, Hodara V, Biraghi P, Muggiasca L, Fenyö EM.

J Infect Dis 1993; 168:207-10.

Neutralizing antibodies and viral characteristics in mother-to-child transmission of HIV-1

Scarlatti G, Leitner T, Hodara V, Halapi E, Rossi P, Albert J, Fenyö EM.

AIDS 1993; 7 Suppl 2:S45-8.

Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic.

Euler Z, Bunnik EM, Burger JA, Boeser-Nunnink BD, Grijsen ML, Prins JM, Schuitemaker H

J Virol. 2011 Jul;85(14):7236-45.

Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies.

van Gils MJ, Bunnik EM, Boeser-Nunnink BD, Burger JA, Terlouw-Klein M, Verwer N, Schuitemaker H

J Virol. 2011 Jul;85(14):6986-95.

Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum.

van Gils MJ, Edo-Matas D, Bowles EJ, Burger JA, Stewart-Jones GB, Schuitemaker H

J Virol. 2011 Aug;85(16):8443-8.

The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcγRI-dependent manner.

Tudor D, Bomsel M.

AIDS. 2011 25: xxxx

Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges.

Bomsel M, Tudor D, Drillet As, Alfsen A, Ganor Y, Roger Mg, Mouz N, Amacker, M Chalifour A, Diomede L, Devillier G, Cong Z, Wei Q, Gao H, Qin C, Yang G, Zurbriggen R, Lopalco L, Fleury S.

Immunity. Feb 2011.

The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcγRI-dependent manner.

Tudor D, Bomsel M.

AIDS. 2011 25: xxxx

Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation.

Brave A, Gudmundsdotter L, Sandström E, Haller K, Hallengärd D, Maltais A-K, King AD, Stout RR, Blomberg P, Höglund U, Hejdeman B, Biberfeld G, Wahren B.

Vaccine. 2010 Nov 29;28(51):8203-9.

Induction of HIV-1-specific cellular and humoral immune responses following immunization with HIV-DNA adjuvanted with activated apoptotic lymphocytes.

Brave A, Johansson U, Hallengärd D, Heidari S, Gullberg H, Wahren B, Hinkula J, Spetz AL.

Vaccine. 2010 Feb 25;28(9):2080-7.

Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level

Bunnik EM, Euler Z, Welkers MRA, Boeser-Nunnink BDM, Grijsen ML, Prins JM, Schuitemaker H.

Nature Medicine. 2010 Sep 16;16(9):995-7.

Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.

Bunnik EM, van Gils MJ, Lobbrecht MS, Pisas L, Nanlohy NM, van Baarle D, van Nuenen AC, Hessell AJ, Schuitemaker H.

J Gen Virol. 2010 May;91(Pt 5):1354-64.

TLR activation pathways in HIV-1-exposed seronegative individuals

Biasin M, Piacentini L, Lo Caputo S, Naddeo V, Pierotti P, Borelli M, Trabattoni D, Mazzotta F, Shearer GM, Clerici M.

J Immunol. 2010 Mar 1;184(5):2710-7.

Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1
Flexible use of CCR5 in the absence of CXCR4 use explains the immune deficiency in HIV-1 infected children.

Cavarelli M, Karlsson I, Ripamonti C, Plebani A, Fenyo EM, Scarlatti G.

AIDS. 2010; 24(16);2527-33.

Beyond IL-17: new cytokines in the pathogenesis of HIV infection

Clerici M.

Current Opinion in HIV and AIDS 2010, 5:184–188

Unravelling the antigenic landscape of the HIV-1 subtype A envelope of an individual with broad cross-neutralizing antibodies using phage display libraries

Dieltjens T, Willems B, Coppens S, Van Nieuwenhove L, Humbert M, Dietrich U, Heyndrickx L, VanHam G, Janssens W.

J Virol Meth. 2010;169:95-102.

Settings of methods for analysis of mucosal antibodies in seminal and vaginal fluids of HIV seropositive subjects from Cambodian and Italian cohorts

Donadoni C, Bisighini C, Scotti L, Diomede L, Ngyen M, Nouhin J, DeSantis L, Zambon A, Ferrari D, Gallotta G, Corrao G, Pancino G, Lopalco L.

Plos ONE 2010;5(3):e9920 doi: 10.1371/journal.pone.00009920

RNA in serum in the course of HIV-1 infection.

Edo-Matas D, van Gils MJ, Bowles EJ, Navis M, Rachinger A, Boeser-Nunnink B, Stewart-Jones GB, Kootstra NA, van 't Wout AB, Schuitemaker H.

Virology. 2010 Sep 30;405(2):492-504.

Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.

Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, Schuitemaker H.

J Infect Dis. 2010 Apr 1;201(7):1045-53.

Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors.

van Gils MJ, Bunnik EM, Burger JA, Jacob Y, Schweighardt B, Wrin T, Schuitemaker H.

J Virol. 2010 Apr;84(7):3576-85.

High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity

van Gils MJ, Edo-Matas D, Schweighardt B, Wrin T, Schuitemaker H.

J Gen Virol. 2010 Jan;91(Pt 1):250-8.

Development of standard operating procedures to obtain longitudinal vaginal specimens from nulliparous rabbits as part of HIV vaccine mucosal immunogenicity studies.

Gomez Roman VR, Vinner L, Grevstad B, Hansen JJ, Wegmann F, Spetz AL, Fomsgaard A.

J Immunol Methods. 2010 Dec 15;363(1):29-41.

Modeling and spectroscopic studies of synthetic diazabicyclo analogues of the HIV-1 inhibitor BMS-378806 and evaluation of their antiviral activity

Legnani L, Colombo D, Cocchi E, Solano L,Villa S, Lopalco L, Asti V, Diomede L, Marinone Albini F, Toma L

Eur J Organic Chemistry. 2010

CCR5: from natural resistance to a new anti-HIV strategy

Lopalco L.

Viruses. 2010;2:574-600 doi: 10.3390/v2020574.

Natural anti-CCR5 antibodies in HIV-infection and –exposure.

Lopalco L.

J Transl Med. 2010;9(Suppl.1):S4.

Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women.

Mestecky J, Wright PF, Lopalco L,4 Staats HF, Kozlowski PA, Moldoveanu Z, Alexander RC,Kulhavy R, Pastori C, Maboko L, Riedner G, Zhu Y, Wrinn T, Hoelscher M.

AIDS Res Hum Retrovir. 2010

Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy

Ozkaya Sahin G, Bowles EJ, Parker J, Uchtenhagen H, Sheik-Khalil E, Taylor S, Pybus OG, Makitalo B, Walther-Jallow L, Spangberg M, Thorstensson R, Achour A, Fenyo EM, Stewart-Jones GBE, Spetz A-L.

PlosPathogens 2010. Open access e1001084

Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy

Piconi S, Trabattoni D, Gori A, Parisotto S, Magni C, Meraviglia P, Bandera A, Capetti A, Rizzardini G, Clerici M.

AIDS. 2010 Aug 24;24(13):1991-2000.

HIV microbicides: state of the art and new perspectives on the development of entry inhibitors

Reina JJ, Bernardi A, Clerici M, Rojo J.

Future Med. Chem. (2010) 2(7), xxx–xxx

Is autoimmunity to CCR5 an escape from the intrusive HIV?

Russo S, Diomede L, Lopalco L.

The Open AutoImmunity Journal. 2010;2:117-126.

Constitutive expression of HIV-VLPs in stably transfected insect cell line for efficient delivery system.

Tagliamonte M, Visciano ML, Tornesello ML, DeStradis A, Buonaguro FM, Buonaguro L.

Vaccine. 2010 Sep 7;28(39):6417-24.

The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific Antibody Dependent Cell Cytotoxicity in a FcgRI-Dependent Manner.

Tudor D, and Bomsel M

AIDS. 2010

HIV Type 1 Subtype A Envelope Genetic Evolution in a Slow Progressing Individual with Consistent Broadly Neutralizing Antibodies

Dieltjens T, Loots N, Vereecken K, Grupping K, Heyndrickx L, Bottieau E, Vanham G, Davis D, Janssens W.

AIDS Res Hum Retroviruses. 2009 Nov;25(11):1165-9.

Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression

van Gils MJ, Euler Z, Schweighardt B, Wrin T, Schuitemaker H.

AIDS. 2009 Nov 27;23(18):2405-14.

Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.

Hinkula J, Walther-Jallow L, Laurén A, Mäkitalo B, Oberg M, Wahren B, Fenyö EM, Spetz AL.

Vaccine. 2009 Oct 30;27(46):6424-31.

FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables

Lucignani G, Orunesu E, Cesari M, Marzo K, Pacei M, Bechi G, Gori A, Gaito S, Clerici M, Chiti A.

Eur J Nucl Med Mol Imaging. 2009 Apr;36(4):640-7.

The “immunologic advantage” of HIV-exposed seronegative individuals

Miyazawa M, Lopalco L, Mazzotta F, Lo Caputo S, Veas F, Clerici M.

AIDS. 2009 Jan 14;23(2):161-75. Review.

Genetic correlates of protection against HIV disease: the ally within

Piacentini L, Biasin M, Fenizia C, Clerici M.

J Intern Med. 2009 Jan;265(1):110-24. Review.

Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection

Tincati C, Biasin M, Bandera A, Violin M, Marchetti G, Piacentini L, Vago GL, Balotta C, Moroni M, Franzetti F, Clerici M, Gori A.

Antivir Ther. 2009;14(3):321-30.

The hunt for an HIV vaccine: time to rethink recent failures.

Boasso A, Shearer GM, Clerici M.

Lancet. 2008 Jun 7;371(9628):1897-8. Review